Tru

ChromaDex’s Tru Niagen® Won the "Most Popular Brand of the Year Award" at China International Natural Health & Nutrition Expo’s (NHNE) Prestigious Nutrition Planet Awards

Retrieved on: 
Monday, October 24, 2022
Biotechnology, Health, Other Health, General manager, Science, NR, NASDAQ, Sinopharm Group, Securities Act of 1933, Natural health product, TGA, CEO, NHNE, Patent, OTC, NAD, European Commission, Tru, CERP, Year, Health Canada, Company, Marketing, Industry, NMN, Therapeutic Goods Administration, Risk, FSANZ, Growth, Annual report, Research, Security (finance), Multimedia, Brazilian Health Regulatory Agency, History, Watsons, Intention, Ageing, VBP, ANVISA, Drug Quality and Security Act, Sale, Fortune Global 500, SEC, JD, Life, Royal commission, Vitamin D, Â, An Act to exempt a particular class of securities from the Securities and Exchange Act, Food, US, Social media, ChromaDex, Food Standards Agency, COVID-19, China National Pharmaceutical Group

Supplementation with Niagen is backed by 20 published and peer-reviewed clinical trials, over 200 published scientific studies and over 30 owned and licensed patents.

Key Points: 
  • Supplementation with Niagen is backed by 20 published and peer-reviewed clinical trials, over 200 published scientific studies and over 30 owned and licensed patents.
  • We are honored to bring such an excellent healthy-aging product to China, said Pan Lei, General Manager of Sinopharm Xingsha.
  • Tru Niagen has also been approved by Health Canada as a Natural Health Product.
  • Sinopharm Xingsha is the health supplement division of Sinopharm Group, a top 100 Chinese nutrition and health consumer brand enterprise, and a key pharmaceutical enterprise in Fujian Province, China.

ChromaDex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement and $5 Million Investment

Retrieved on: 
Tuesday, October 11, 2022
Research, Vitamins, Supplements, Fitness & Nutrition, Alternative Medicine, Food, Beverage, Health, General Health, Retail, Science, Tru, U.S. Securities and Exchange Commission, Dietary supplement, Sale, SEC filing, SEC, Achievement, Science, NR, NASDAQ, Research, Security (finance), Private Securities Litigation Reform Act, Company, Health, CEO, Safety, ChromaDex, Forward-looking statement, Respiration (physiology), Ageing, FDA, NAD, Human, Functional food, Pharmaceutical industry

ChromaDex Corp. (NASDAQ:CDXC) (the Company or ChromaDex) a global bioscience company dedicated to healthy aging, announced today a new long term commercial license and supply agreement with Nestl Health Science, a global leader in science-based nutritional health solutions.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC) (the Company or ChromaDex) a global bioscience company dedicated to healthy aging, announced today a new long term commercial license and supply agreement with Nestl Health Science, a global leader in science-based nutritional health solutions.
  • The agreement provides Nestl Health Science the non-exclusive right to manufacture, market, distribute, and sell products using nicotinamide riboside or NR, trademarked Niagen, under its brands world-wide, except where ChromaDex has existing exclusive distribution agreements.
  • Consideration for the rights granted to Nestl Health Science under the agreement include a $1.975 million initial purchase of Niagen.
  • Nestl Health Science, a leader in the science of nutrition, is a globally managed business unit of Nestl.

ChromaDex Finalizes Commercial Joint-Venture in Asia and Announces $3.1 Million Private Placement of Common Stock

Retrieved on: 
Monday, October 3, 2022
Men, Other Health, General Health, Other Retail, Lifestyle, Specialty, Consumer, Fitness & Nutrition, Retail, Women, Seniors, Vitamins, Supplements, Health, China National Pharmaceutical Group, ChromaDex, NAD, Blue, OTC, NASDAQ, Tru, Human, News, Fortune Global 500, Time, History, Private Securities Litigation Reform Act, Territory, JV, Research, Sinopharm Group, Securities Act of 1933, Industry, VBP, The Act, CEO, Twitter, FDA, Phytochemical, Human body, NR, Ageing, U.S. Securities and Exchange Commission, Science, Prospectus, Sale, Security (finance), Forward-looking statement, Vitamin D, BlueHat, Company, Cryptocurrency

The Company also announced that it entered into a securities purchase agreement for the sale of $3.1 million of its common stock in a private placement.

Key Points: 
  • The Company also announced that it entered into a securities purchase agreement for the sale of $3.1 million of its common stock in a private placement.
  • The private placement was led by existing strategic investors, and included an investment by ChromaDex CEO, Rob Fried.
  • The private placement is expected to close on or about October 7, 2022, subject to the satisfaction of customary closing conditions.
  • The shares of common stock being sold in the private placement will not have been registered under the Securities Act of 1933, as amended (the Act).

Sinopharm Xingsha to Introduce ChromaDex’s Tru Niagen® at Major Mainland China Trade Show, China International Natural Health & Nutrition Expo (NHNE)

Retrieved on: 
Monday, September 19, 2022
Fitness & Nutrition, Health, COVID-19, Ageing, Sale, Food, Securities Act of 1933, NAD, NR, Intention, ANVISA, NHNE, Company, European Commission, Therapeutic Goods Administration, TGA, Growth, Tru, Industry, Brazilian Health Regulatory Agency, ChromaDex, Risk, History, Food Standards Agency, CEO, Health Canada, WeChat, BlueHat, NMN, Annual report, Natural health product, FSANZ, Watsons, General manager, Science, US, NASDAQ, An Act to exempt a particular class of securities from the Securities and Exchange Act, Research, Security (finance), R, Royal commission, SEC, Pleasure, Awareness, Marketing, Patent, CERP, JD, Dietary supplement, Video game

ChromaDex Corp. (NASDAQ:CDXC) today announced that Sinopharm Xingsha will debut Tru Niagen at the major mainland China trade show, China International Natural Health & Nutrition Expo (NHNE), which kicks off Tuesday, September 20, in Shanghai.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC) today announced that Sinopharm Xingsha will debut Tru Niagen at the major mainland China trade show, China International Natural Health & Nutrition Expo (NHNE), which kicks off Tuesday, September 20, in Shanghai.
  • NHNE is Asias largest expo on natural health and nutrition products, with over 100,000 distributors and retailers.
  • It is considered the best platform to help global manufacturers of health food and nutrition promote their brands and expand business channels in China, where Tru Niagen is currently sold cross-border.
  • We are grateful to Sinopharm Xingsha for leading the debut of Tru Niagen at NHNE.

ELISE raises $14.8 million Series A to scale connected engineering

Retrieved on: 
Wednesday, September 7, 2022
Technology, Vehicle Technology, Automotive, Engineering, Transport, Automotive Manufacturing, Other Automotive, Software, Manufacturing, Logistics, Supply Chain Management, Plaid, Cherry Venture, Software, Engineering, CEO, Sustainability, Premium AEROTEC, EDAG, Miele, Life, Zalando, Solution, Alfred Wegener Institute for Polar and Marine Research, BMW, Flixbus, Toyota, IPO, Hyundai, MAN Truck & Bus, Spark Capital, Forto, Investment, Multimedia, Method, Flink, Transport, Tru, Internet, Silicon, Twitter, Algorithm, B2B, Face, Development, Industry, Hyundai Motor Group, Wayfair, 3D printing, Financial services, Controlled-access highway, Airbus, Graphcore, Oculus, Carta, Tekion, Spotify, TurnTide, Discord

ELISE , the Germany-based connected engineering platform, has closed its Series A financing round of $14.8 million.

Key Points: 
  • ELISE , the Germany-based connected engineering platform, has closed its Series A financing round of $14.8 million.
  • "This new investment will allow us to make significant progress towards our goal of becoming the low-code standard in engineering.
  • "ELISE has made the idea of connected engineering part of everyday life at renowned companies including BMW, Mercedes-Benz Group and Airbus.
  • The product | ELISE stands for Connected Engineering and is the first open low-code development platform of its kind transforming the product development process.

ChromaDex Announces Partnership with MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen® and Tru Niagen® PRO into Brazil

Retrieved on: 
Thursday, September 1, 2022
Biotechnology, General Health, Pharmaceutical, Health, Partnership, COVID-19, Patient, CEO, HCP, OTC, Security (finance), HCPS, Securities Act of 1933, Research, NASDAQ, NR, Ageing, CERP, Nicotinamide mononucleotide, Brazilians, Sale, NMN, An Act to exempt a particular class of securities from the Securities and Exchange Act, ChromaDex, Policy, Risk, Food, ANVISA, Royal commission, Therapeutic Goods Administration, FSANZ, SEC, Health Canada, Natural health product, TGA, Vitamin B3, NAD, Â, Company, Compliance, History, Tru, Founder, Annual report, European Commission, Acquisition, Industry, Growth, Marketing, Food Standards Australia New Zealand, Online shopping

ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with MyPharma2Go to conduct cross-border sales of Tru Niagen and Tru Niagen PRO in Brazil, the first Latin American country to welcome the brand.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with MyPharma2Go to conduct cross-border sales of Tru Niagen and Tru Niagen PRO in Brazil, the first Latin American country to welcome the brand.
  • The cross-border distribution strategy allows for Tru Niagen 300mg 30 count bottles, Tru Niagen 300mg 90 count bottles and Tru Niagen 300mg 30 count Stickpacks to be purchased by consumers looking to age healthier.
  • We are pleased to work with MyPharma2Go to introduce the healthy aging benefits of Tru Niagen to Brazil, said Rob Fried, CEO of ChromaDex.
  • Tru Niagen, Tru Niagen PRO and Tru Niagen Stickpacks are now available for sale in the Brazilian market on several cross-border marketplaces including www.saudecelular.com.br , www.mypharma2go.com , www.mundihealth.com and through HCP in-person sales.

ChromaDex Corporation Reports Second Quarter 2022 Financial Results

Retrieved on: 
Wednesday, August 10, 2022
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, U.S. Securities and Exchange Commission, Compte rendu, Securities Act of 1933, Investor relations, Forward-looking statement, Growth, Securities Exchange Act of 1934, SEC, Walmart, Security (finance), Environment, Watson, NR, History, Annual report, Research, Marketing, EBITDA, NAD, Company, COVID-19, Twitter, Ageing, Human body, NASDAQ, GAAP, Replay, News, Tru, Webcast, Phytochemical, Human, Conference, ChromaDex, Efficiency, Tutoring, Grocery store, Pharmaceutical industry, Communications satellite

ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2022.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2022.
  • Total net sales and Tru Niagen net sales remained relatively flat year over year excluding the initial shelf stocking sales to Wal-Mart in the second quarter of 2021.
  • Results of operations for the three months ended June 30, 2022 compared to the prior year quarter
    For the three months ended June 30, 2022 (Q2 2022), ChromaDex reported net sales of $16.7 million, a decrease $1.0 million or (5)% compared to the second quarter of 2021 (Q2 2021).
  • The Company expects to approach cash flow break-even in the third quarter and be cash flow break-even or better in the fourth quarter of 2022.

ChromaDex Partners with Juvenis for Cross-Border Sales of Tru Niagen® into South Korea

Retrieved on: 
Thursday, June 2, 2022
Health, Genetics, Other Science, Research, Science, Biotechnology, Science, Entrepreneurship, Gmarket, NAD, Korea, US, Company, Brazilian Health Regulatory Agency, Research, Therapeutic Goods Administration, Marketing, City of Hope National Medical Center, NR, ANVISA, Securities Act of 1933, Tru, Food, Vitamin B3, United Nations, Auction, Annual report, TGA, Nicotinamide mononucleotide, CEO, Security (finance), Partnership, Natural health product, CERP, City, Metabolism, Sale, Growth, Health Canada, South Korea, FSANZ, COVID-19, NMN, Risk, NASDAQ, SEC, Industry, Royal commission, European Commission, History, ChromaDex, Food Standards Agency, Ageing, An Act to exempt a particular class of securities from the Securities and Exchange Act, Pharmaceutical industry, Diabetes, Campeonato Nacional de Juvenis

ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with Juvenis to conduct cross-border sales of Tru Niagen in South Korea.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with Juvenis to conduct cross-border sales of Tru Niagen in South Korea.
  • Tru Niagen is one of Amazons top-selling brands in the Vitamin B3 category for boosting NAD+ levels and features ChromaDexs proprietary ingredient, Niagen (patented nicotinamide riboside or NR).
  • It is our goal to provide global access to Tru Niagen and are thrilled to partner with Juvenis to bring its proven benefits to South Korea, said Frank Jaksch, Co-Founder and Executive Chairman of ChromaDex.
  • We are pleased to execute a partnership with ChromaDex for the South Korean market, said Dongyeon Kim, CEO of Juvenis.

ChromaDex Announces Agreement to Launch Commercial Joint Venture in Mainland China

Retrieved on: 
Thursday, May 19, 2022
Health, Other Health, Other Science, Research, Science, Biotechnology, Company, SAMR, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Phytochemical, ChromaDex, News, Agreement, Territory, NASDAQ, JV, NAD, Research, Tru, Forward-looking statement, Human, Product, Ageing, Security (finance), Twitter, NR, Human body, 8-K, CEO

ChromaDex Corp. (NASDAQ:CDXC) (the Company) a global bioscience company dedicated to healthy aging, today announced it has entered into an agreement (the JV Agreement) to establish a joint venture through its wholly owned subsidiary ChromaDex Asia Limited (the JV or ChromaDex Asia).

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC) (the Company) a global bioscience company dedicated to healthy aging, today announced it has entered into an agreement (the JV Agreement) to establish a joint venture through its wholly owned subsidiary ChromaDex Asia Limited (the JV or ChromaDex Asia).
  • Upon establishment of the JV, membership of ChromaDex Asia will collectively consist of the Company; Crystal Lake Developments Limited; Pioneer Idea Holdings Limited; and Hong Kong Taikuk (China) Group Limited.
  • Health food registration is a key regulatory step required to be able to broadly market and distribute Tru Niagen products in China.
  • The establishment of this joint venture marks an expansion milestone in ChromaDexs China strategy and sets the necessary foundation to advance sales of Tru Niagen in this key market, said Rob Fried, CEO of ChromaDex.

Hilton Summer Road Trip Hacks Pave the Way for Convenient and Stress-Free Travel

Retrieved on: 
Monday, May 16, 2022
Lodging, Travel, People, Smartphone, Hilton Garden Inn, Hilton Worldwide, Family, Multimedia, Human, Microwave, Fortune, Digital, Wakefield, Breakfast, Triple point, Eating, OnePoll, Light, Bézier curve, Meal, Partnership, PETS, Time, Tru, Embassy Suites by Hilton, Instagram, YouTube, Travel, Dow Jones, LinkedIn, HLT, Twitter, Growth, Hampton by Hilton, NYSE, Hand, Connecting Rooms, PTO, Hotel, Restaurant, Online gambling, Homewood Suites by Hilton, Facebook

Plus, it satisfies the need to go to a restaurant, eliminating travel and wait times vs. dining out while on the go.

Key Points: 
  • Plus, it satisfies the need to go to a restaurant, eliminating travel and wait times vs. dining out while on the go.
  • According to a recent Hilton2 survey, 55% of Americans who are pet owners are likely to travel with their pet this summer.
  • For a limited time, Hilton Honors members can also rack up Points for summer travel faster with the More Nights, More Points promotion.
  • For more information or to book your summer getaway with Hilton, please visit stories.hilton.com or www.hilton.com .